NCT02482168 2023-12-20Study of the CD40 Agonistic Monoclonal Antibody APX005MApexigen America, Inc.Phase 1 Completed43 enrolled
NCT03597282 2020-09-03A Personal Cancer Vaccine (NEO-PV-01) and APX005M or Ipilimumab With Nivolumab in Patients With Advanced MelanomaBioNTech SEPhase 1 Terminated22 enrolled